Featured Press Releases

Innorna Announces FDA Grants Rare Pediatric Disease and Orphan Drug Designations to IN013 for Wilson Disease Treatment

Innorna Announces FDA Grants Rare Pediatric Disease and Orphan Drug Designations to IN013 for Wilson Disease Treatment

TIVDAK® Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

TIVDAK® Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

  • 29 Apr 2024

Genmab A/S announced the U.S. Food and Drug Administration (FDA) has approved the supplemental...

Hanmi Pharmaceutical Launches

Hanmi Pharmaceutical Launches 'Aditams' in Mexico, Expanding into Latin America

Cytoki Pharma Announces Positive Phase 1 Data Showing Potential of CK-0045 to Improve Cardiometabolic Risk Factors

Cytoki Pharma Announces Positive Phase 1 Data Showing Potential of CK-0045 to Improve Cardiometabolic Risk Factors

In Europe, Samsung Bioepis begins the commercialization of BYOOVIZ®, a biosimilar to Lucentis (Ranibizumab)

In Europe, Samsung Bioepis begins the commercialization of BYOOVIZ®, a biosimilar to Lucentis (Ranibizumab)

A new real-world case series examines re-induction with ADSTILADRIN in clinical practice

A new real-world case series examines re-induction with ADSTILADRIN in clinical practice

PHC Launched MTR-OPC1-PW Interface Board in September to Strengthen Data Linkage Between Equipment and Customer Systems

PHC Launched MTR-OPC1-PW Interface Board in September to Strengthen Data Linkage Between Equipment and Customer Systems

  • PHC Corporation
  • 08 Sep 2026
Avenacy Launched Cyclophosphamide for Injection, USP in the U.S. Market

Avenacy Launched Cyclophosphamide for Injection, USP in the U.S. Market

  • Release Versions
  • 07 Sep 2026
New HCPCS Billing Code Enables Medicare Reimbursement for Lasix® ONYU When Furnished Incident to a Physician’s Service

New HCPCS Billing Code Enables Medicare Reimbursement for Lasix® ONYU When Furnished Incident to a Physician’s Service

  • SQ Innovation
  • 02 Sep 2026
Jarrow Formulas® Launches Gut & Protein Optimizer and NMN 300 mg to Support Protein Absorption, Cellular Energy, and Healthy Aging

Jarrow Formulas® Launches Gut & Protein Optimizer and NMN 300 mg to Support Protein Absorption, Cellular Energy, and Healthy Aging

  • Jarrow Formulas
  • 02 Sep 2026
Abbott Launched the First and Only Ready-to-Feed Liquid Infant Formula Made with Whole Milk in the U.S. at a Price Similar to Its Existing Similac Powdered Formula

Abbott Launched the First and Only Ready-to-Feed Liquid Infant Formula Made with Whole Milk in the U.S. at a Price Similar to Its Existing Similac Powdered Formula

  • Abbott
  • 01 Sep 2026
Karyopharm Files Supplemental New Drug Application with FDA for XPOVIO® (Selinexor) in Combination with Ruxolitinib for the Treatment of Myelofibrosis

Karyopharm Files Supplemental New Drug Application with FDA for XPOVIO® (Selinexor) in Combination with Ruxolitinib for the Treatment of Myelofibrosis

  • Karyopharm Therapeutics Inc.
  • 31 Aug 2026

Most Popular
September   2026
M T W T F S S
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30        

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.